Table 2. Changes of BCVA and CMT between the two groups.
|
BCVA |
CMT |
|||||
|---|---|---|---|---|---|---|
| IVB group | IVB/STA group | P-value | IVB group | IVB/STA group | P-value | |
| Baseline | 0.60±0.24 | 0.65±0.43 | 0.642 | 510.35±185.36 | 468.22±159.26 | 0.607 |
| 1 month | 0.42±0.24 | 0.46±0.35 | 0.961 | 291.48±100.19 | 233.33±79.95 | 0.015 |
| 3 months | 0.44±0.28 | 0.42±0.32 | 0.615 | 265.35±106.85 | 233.22±57.09 | 0.742 |
| 6 months | 0.38±0.29 | 0.41±0.35 | 0.973 | 246.48±88.00 | 217.83±42.64 | 0.639 |
Abbreviations: BCVA, best-corrected visual acuity; CMT, central macular thickness; IVB group, intravitreal bevacizumab injection alone; IVB/STA group, combines intravitreal bevacizumab with subtenon triamcinolone acetonide injection.
P-value: Mann–Whitney U-test.